Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients
    Meeting Abstract

    Abdel-Wahab, O. I.; Diamond, E. L.; Patel, M.; Holley, V. R.; Cabrilo, G.; Rampal, R.; Hassaine, L.; Kosco, K.; Baselga, J.; Kurzrock, R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Journal Article

    Yeung, D. T.; Mauro, M. J.
    Hematology-American Society of Hematology Education Program (2014)

    Fulltext@MSK | Save
  • Goals for chronic myeloid leukemia TK inhibitor treatment: How little disease is too much?
    Journal Article

    Mauro, M. J.
    Hematology-American Society of Hematology Education Program (2014)

    Fulltext@MSK | Save
  • Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease
    Journal Article

    Zingone, A.; Wang, W.; Corrigan-Cummins, M.; Wu, S. P.; Plyler, R.; Korde, N.; Kwok, M.; Manasanch, E. E.; Tageja, N.; Bhutani, M.; more...
    Cytokine (2014)

    Fulltext@MSK | Save
  • Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition
    Journal Article

    Mehta, N.; Schòˆder, H.; Chiu, A.; Schoolmeester, J. K.; Portlock, C.
    BMJ Case Reports (2014)

    Fulltext@MSK | Save
  • The role of MicroRNAs in hematopoietic stem cells and leukemia development
    Book Section

    Yalcin, S.; Chung, S. S.; Park, C. Y.
    In Singh, S. R.; Rameshwar, P. (Eds.) MicroRNA in Development and in the Progression of Cancer (2014)

    Fulltext@MSK | Save
  • Oncogenic RAF mutants that signal as functional dimers are resistant to current RAF inhibitors but sensitive to a novel inhibitor of RAF dimer kinase activity
    Meeting Abstract

    Yao, Z.; Torres, M.; Wei, M.; Hanrahan, A.; Abdel-Wahab, O.; Solit, D.; Luo, L. S.; Poulikakos, P.; Rosen, N.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Investigations into the tumor specific regulation of HER2 by Grp94 in breast cancer
    Meeting Abstract

    Yan, P.; Patel, H.; Yang, C.; Taldone, T.; Chiosis, G.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies
    Meeting Abstract

    Stein, E.; Tallman, M.; Pollyea, D. A.; Flinn, I. W.; Fathi, A. T.; Stone, R. M.; Levine, R. L.; Agresta, S.; Schenkein, D.; Yang, H.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Meeting Abstract

    Schwartz, S.; Carver, B. S.; Wongvipat, J.; Rodrik-Outmezguine, V. ; Destanchina, E.; Trigwell, C.; Barry, S.; Baselga, J.; Chandarlapaty, S.; Scher, H. I.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save